Among key corporate earnings, Lupin, Adani Enterprises and Emami are scheduled to announce their quarter ended 31 March 2015 results today, 13 May 2015.
Ashok Leyland's net profit fell 36.71% to Rs 229.97 crore on 46.6% rise in total income to Rs 4542.95 crore in Q4 March 2015 over Q4 March 2014. The result was announced after market hours yesterday, 12 May 2015.
Credit Analysis and Research's (CARE) net profit fell 15.03% to Rs 35.09 crore on 3% decline in total income to Rs 81.04 crore in Q4 March 2015 over Q4 March 2014. The result was announced after market hours yesterday, 12 May 2015.
Meanwhile, CARE announced after market hours yesterday, 12 May 2015, that Mauritian regulator, Financial Services Commission (FSC) vide its letter dated 7 May 2015 accorded its approval for a Credit Rating Agency licence under Section 14 of the Financial Services Act, 2007 to CARE Ratings (Africa), a subsidiary of the company in Mauritius.
Torrent Power's consolidated net profit rose 2.34% to Rs 181.61 crore on 20.13% growth in total income to Rs 2742.72 crore in Q4 March 2015 over Q4 March 2014. The result was announced after market hours yesterday, 12 May 2015.
Jubilant Life Sciences' consolidated net profit fell 56.75% to Rs 42.73 crore on 1.59% decline in total income to Rs 1542.37 crore in Q4 March 2015 over Q4 March 2014. The result was announced after market hours yesterday, 12 May 2015.
In Q4 March 2015, income from operations of the pharmaceuticals segment was at Rs 763 crore, contributing 50% to the revenue mix. The segment earnings before interest, tax, depreciation and amortisation (EBITDA) stood at Rs 200 crore, with EBITDA margins at 26.2%.
In Q4 March 2015, income from operations of the Life Science Ingredients segment stood at Rs 774 crore, contributing 50% to the revenue mix. The segment EBITDA stood at Rs 66 Crore, with EBITDA margins at 8.5%.
In Q4 March 2015, revenues from North America stood at Rs 621 crore, contributing 40% to the overall revenues. Revenues from Europe and Japan stood at Rs 284 crore, contributing 19% to the revenue mix. Domestic revenues grew 5% YoY and stood at Rs 422 crore, thus contributing 27% to the overall mix. Revenues in rest of world including China was at Rs 209 crore, thus contributing 14% to the overall mix.
In its outlook for year ended 31 March 2016 (FY 2016), company said revenue growth is expected to be driven by Pharmaceuticals segment primarily led by improved performance in Radiopharmaceuticals, normalization of its CMO business operations and growth in generics business through new product and new market launches. Life Science Ingredients segment is expected to deliver better results due to improved operational efficiency and growth in Nutritional Products and Fine Ingredients businesses.
Commenting on the company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said: Sustained strong performance in Radiopharmaceuticals business and normalisation of CMO operations supported revenue growth in the pharmaceuticals segment. In Life Science Ingredients, Nutritional Products and Fine Ingredients recorded healthy growth. Going forward, the company expect the Pharmaceuticals segment to drive revenue growth with improvement in profitability in key businesses across both segments. The company also expect the management consolidation to drive the businesses in a focussed manner to improve the operating performance. The company will also continue its endeavours to strengthen the balance sheet.
Jubilant Life Sciences announced after market hours yesterday, 12 May 2015, that the board of directors of the company at its meeting held on 12 May 2015, has recommended a dividend of Rs 3 per share for the year ended 31 March 2015 (FY 2015).
L&T will be watched. With respect to news article titled "L&T, Hyundai Heavy Ink Pact to Build LNG Carriers", L&T clarified after market hours yesterday, 12 May 2015, that at this stage L&T and Hyundai Heavy Industries have only signed a Memorandum of Understanding to enable participation in expected GAIL tender for LNG carrier. This is in anticipation of a possible retendering by GAIL to invite bids from potential ship owners for chartering of LNG carriers.
Sobha's consolidated net profit fell 12.39% to Rs 61.50 crore on 19.24% decline in total income to Rs 509.30 crore in Q4 March 2015 over Q4 March 2014. The result was announced after market hours yesterday, 12 May 2015.
Commenting on outlook for year ended 31 March 2016 (FY 2016), Mr, J.C. Sharma, Vice Chairman and Managing Director, Sobha said that considering the present macro-economic environment and industry absorption levels, the company is targeting to sell 4 million square feet of new area valued at Rs 2600 crore during FY 2016.
Sobha announced after market hours yesterday, 12 May 2015, that the board of directors of the company at its meeting held on 12 May 2015 inter alia, have recommended dividend of Rs 7 per equity share for the year ended 31 March 2015 (FY 2015).
Powered by Capital Market - Live News
